ORYZON Announces Expansion of its Scientific Advisory Board

BARCELONA, SPAIN and CAMBRIDGE MA.

• Congregates world known experts in Alzheimer’s disease

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced key additions to its Scientific Advisory Board (SAB) to reinforce the capabilities of its epigenetic drug ORY-2001 in neurodegenerative and neuroinflammatory diseases, a drug for which a Phase I clinical trial is expected to be completed this year.

Click here to see the full Press Release